Video

Continuing Treatment in Postmenopausal Women with Osteoporosis

Author(s):

According to Lori Fitzpatrick, MD, additional findings showed that regardless of age, whether or not patients have had vertebral or non-vertebral fractures, treatment with abaloparatide worked.

During the 2016 ACR/ARHP meeting, Lori Fitzpatrick, MD, explained, "It's interesting, that even though we were head to head with another anabolic agent, we actually had better increases in BMD at cortical sites (total hip and the femoral hip), than teriparatide, and we also had reduction in fractures. However, we actually had a 43% reduction in non vertebral fractures compared to placebo." According to Fitzpatrick, additional findings showed that, regardless of age, whether or not patients had vertebral or non-vertebral fractures, treatment with abaloparatide worked.

Related Videos
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.